Tuesday, January 8, 2013
Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase IIb study testing EPI-743 in patients with Friedreich's ataxia. The six-month study, expected to be followed by an extension phase, will enroll patients between the ages of 18 and 45 who possess genetic confirmation of Friedreich's ataxia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.